Clinical trial · Observational
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
NCT06798805CI-TRIAL-00085217active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study the aim is to investigate the pathogenetic role of extracellular vesicles and senescence in Myeloproliferative Neoplasms. In particular, the goal of this project is to identify possible EV-based biomarkers of senescence according to gender, which are disease-specific, biology-related, and predictive of short-term outcome in terms of Event-Free Survival and to define personalized targets for new therapeutic approaches.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia (ET) | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.85 |
| Myelofibrosis (MF) | Primary Myelofibrosis | ALIAS | 0.85 |
| Polycythemia Vera (PV) | Polycythemia Vera | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Plasma extracellular vesicle characterization
- timeFrame
- 2 years
- description
- Comparison of concentration (particles/mL), phenotype, and cargo between extracellular vesicles from patients and healthy donors.
- measure
- Validation of extracellular vesicles as biomarker
- timeFrame
- 2 years
- description
- Correlation of extracellular vesicles' characterization data with markers of disease aggressiveness.
Secondary outcomes (2)
- measure
- Cell culture-derived extracellular vesicle characterization
- timeFrame
- 2 years
- description
- Comparison of the phenotype of extracellular vesicles derived from the supernatant of selected immune cells cultured in the presence or absence of inflammatory factors.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria for patients: * age ≥ 18 years. * patients with WHO2017-defined diagnosis of Myeloproliferative Neoplasms. * patients at first diagnosis. * Informed consent signed. Exclusion criteria for patients: \- patients with concomitant second neoplasia Inclusion criteria for Healthy Donors: * age ≥ 18 years. * Informed consent signed. Exclusion criteria for Healthy Donors: \- Healthy Donors with neoplasia.
References
Publications (0)
Data not yet available
No reference posted for this study.